Singh S, et al. - Researchers undertook this analysis to assess the impacts of the long-acting muscarinic antagonist umeclidinium (Umec) and long-acting β₂-agonist vilanterol (Vi) separately and in combination on static hyperinflation, exercise endurance time (EET), and their relationship in patients with chronic obstructive pulmonary disease (COPD). In comparison with Umec or Vi, the dual bronchodilator Umec/Vi showed greater improvements in static hyperinflation markers and significant improvements in exercise endurance. Notably, findings demonstrated no direct link between static hyperinflation and exercise endurance.